Clinical Trial Update: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of alectinib in ALK-rearranged non-small cell lung cancer completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-02-12